Herold, Kevan C.

Genetics, pathogenesis and clinical interventions in type 1 diabetes

Bluestone, J. A., Herold, K., & Eisenbarth, G. (2010) · Nature

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 1,265

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus

Herold, K. C., Hagopian, W., Auger, J. A., Poumian-Ruiz, E., Taylor, L., Donaldson, D., Gitelman, S. E., Harlan, D. M., Xu, D., Zivin, R. A., et al. (2002) · New England Journal of Medicine

Diabetes and associated disordersDiabetes Management and Research

Cited by 1,222

Staging presymptomatic type 1 diabetes: A scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association

Insel, R. A., Dunne, J. L., Atkinson, M. A., Chiang, J. L., Dabelea, D., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Krischer, J. P., Lernmark, Å., et al. (2015) · Diabetes Care

Diabetes and associated disordersDiabetes Management and Research

Cited by 1,216

An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes

Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., et al. (2019) · New England Journal of Medicine

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 1,189

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

Bluestone, J. A., Buckner, J. H., Fitch, M., Gitelman, S. E., Gupta, S., Hellerstein, M. K., Herold, K. C., Lares, A., Lee, M. R., Li, K., et al. (2015) · Science Translational Medicine

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 1,033

Reprogramming human T cell function and specificity with non-viral genome targeting

Roth, T. L., Puig-Saus, C., Yu, R., Shifrut, E., Carnevale, J., Li, P. J., Hiatt, J., Saco, J., Krystofinski, P., Li, H., et al. (2018) · Nature

CRISPR and Genetic EngineeringCAR-T cell therapy research

Cited by 839

Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation

Ramasamy, R., Vannucci, S. J., Yan, S. S. D., Herold, K., Yan, S. F., & Schmidt, A. M. (2005) · Glycobiology

Advanced Glycation End Products researchPotato Plant Research

Cited by 834

Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors

Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes

Cancer Immunotherapy and BiomarkersDiabetes and associated disorders

Cited by 590

Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial

Sherry, N., Hagopian, W., Ludvigsson, J., Jain, S. M., Wahlen, J., Ferry, R. J., Bode, B., Aronoff, S., Holland, C., Carlin, D., et al. (2011) · The Lancet

Diabetes and associated disordersDiabetes Management and Research

Cited by 493

C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function

Palmer, J. P., Fleming, G. A., Greenbaum, C. J., Herold, K. C., Jansa, L. D., Kolb, H., Lachin, J. M., Polonsky, K. S., Pozzilli, P., Skyler, J. S., et al. (2004) · Diabetes

Diabetes and associated disordersDiabetes Management and Research

Cited by 491

Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals

Sims, E. K., Bundy, B. N., Stier, K., Serti, E., Lim, N., Long, S. A., Geyer, S. M., Moran, A., Greenbaum, C. J., Evans-Molina, C., et al. (2021) · Science Translational Medicine

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 377

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

Wherrett, D. K., Bundy, B., Becker, D. J., DiMeglio, L. A., Gitelman, S. E., Goland, R., Gottlieb, P. A., Greenbaum, C. J., Herold, K. C., Marks, J. B., et al. (2011) · The Lancet

Diabetes and associated disordersDiabetes Management and Research

Cited by 371

Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes

Battaglia, M., Ahmed, S., Anderson, M. S., Atkinson, M. A., Becker, D., Bingley, P. J., Bosi, E., Brusko, T. M., DiMeglio, L. A., Evans-Molina, C., et al. (2020) · Diabetes Care

Diabetes and associated disordersDiabetes Management and Research

Cited by 351

Fall in C-Peptide During First 2 Years From Diagnosis

Greenbaum, C. J., Beam, C. A., Boulware, D., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lachin, J. M., McGee, P., Palmer, J. P., Pescovitz, M. D., et al. (2012) · Diabetes

Diabetes and associated disordersDiabetes Management and Research

Cited by 319

Teplizumab and β-cell function in newly diagnosed type 1 diabetes

Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine

Diabetes and associated disordersDiabetes Management and Research

Cited by 273

Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes

Long, S. A., Thorpe, J., DeBerg, H. A., Gersuk, V., Eddy, J. A., Harris, K. M., Ehlers, M., Herold, K. C., Nepom, G. T., & Linsley, P. S. (2016) · Science Immunology

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 250

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes

Hagopian, W., Ferry, R. J., Sherry, N., Carlin, D., Bonvini, E., Johnson, S., Stein, K. E., Koenig, S., Daifotis, A. G., Herold, K. C., et al. (2013) · Diabetes

Diabetes and associated disordersDiabetes Management and Research

Cited by 247

Type 1 diabetes: translating mechanistic observations into effective clinical outcomes

Herold, K. C., Vignali, D. A. A., Cooke, A., & Bluestone, J. A. (2013) · Nature Reviews Immunology

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 237

How Does Type 1 Diabetes Develop?

Atkinson, M. A., Bluestone, J. A., Eisenbarth, G. S., Hebrok, M., Herold, K. C., Accili, D., Pietropaolo, M., Arvan, P. R., Von Herrath, M., Markel, D. S., et al. (2011) · Diabetes

Diabetes and associated disordersPancreatic function and diabetes

Cited by 232

Quantifying the effect of experimental perturbations at single-cell resolution

Burkhardt, D. B., Stanley, J. S., Tong, A., Perdigoto, A. L., Gigante, S. A., Herold, K. C., Wolf, G., Giraldez, A. J., van Dijk, D., & Krishnaswamy, S. (2021) · Nature Biotechnology

Single-cell and spatial transcriptomicsGene expression and cancer classification

Cited by 226

Treatment of patients with new onset type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years

Herold, K. C., Gitelman, S., Greenbaum, C., Puck, J., Hagopian, W., Gottlieb, P., Sayre, P., Bianchine, P., Wong, E., Seyfert-Margolis, V., et al. (2009) · Clinical Immunology

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 219

Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of β-Cells

Sherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology

Diabetes and associated disordersPancreatic function and diabetes

Cited by 169

Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial

Russell, W. E., Bundy, B. N., Anderson, M. S., Cooney, L. A., Gitelman, S. E., Goland, R. S., Gottlieb, P. A., Greenbaum, C. J., Haller, M. J., Krischer, J. P., et al. (2023) · Diabetes Care

Diabetes and associated disordersT-cell and B-cell Immunology

Cited by 108

Changing the landscape for type 1 diabetes: the first step to prevention

Dayan, C. M., Korah, M., Tatovic, D., Bundy, B. N., & Herold, K. C. (2019) · The Lancet

Diabetes and associated disordersDiabetes Management and Research

Cited by 96